Starting with autoimmune diseases. A $42 billion market opportunity.

A majority of patients prescribed the world’s largest selling drug class, anti-TNF therapy don’t actually respond to treatment.

PrismRA is a blood based test that predicts patients not likely to respond to anti-TNF therapy before the drug is prescribed so non-responders can access alternative effective drugs from day one.

View Prism RA

We use real world clinico-genomic data from tested patients to enable precision immunology.

As our database grows to thousands of patients, we partner with pharma to develop drugs that can be prescribed to biologically similar patients with high response rates.